GrandPharma (China) Co. Ltd

Grandpharma (originally as Wuhan Pharmaceutical Company) was founded in 1939 as a medical material factory for Eighth Route Army during the WW II. Through the merger into China Grand Enterprises in 2002, Grandpharma has been evolving its business from bulk API to high-end ingredients production, transforming itself upstream to producing innovative drugs and downstream to producing pharmaceutical preparations. After becoming the main enterprise of Hong Kong-listed parent company (HK: 00512) and through acquisition of 18 domestic and international companies, Grandpharma has now become China's largest ophthalmology & otorhinolaryngology Pharmaceutical Group, one of a few China's cardiovascular first-aid medicine provider and the world's top drug coated balloon technology owner. Grandpharma is now actively expanding its business in the field of interventional therapy for cancer. Headquartered in Wuhan, Grandpharma has subsidiaries distributed across Hubei Province and in Beijing, Tianjin, Xi’an, Zhuhai. Our products are sold to dozens of different countries and regions around Asia, Europe, and America. The annual sales revenue is expected to reach 4 billion. We have over 7,000 employees, including over 2,000 in sales promotion, and an independent R&D center consisted of over 300 professionals. In addition, we have hired world-renowned pharmaceutical experts from U.S., New Zealand, Australia and India, etc. The successful commercialized production of L – cysteine and citrulline through microbial fermentation, which was introduced by Dr. Hui Ouyang, the chief bioengineering scientist in Grandpharma, has fulfilled the gap of large production of cysteine in China.